Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Only been 35 minutes since market opened, can't believe some are packing it in for the day. Even if .53 takes an hour to hammer thru, still have lots of time left.
No matter what happens in the morning, I expect afternoons to be pretty good for the most part.
I can understand their lack of knowledge about B as that is not their bailiwick.
If I was in the Army, I probably wouldn't know what is going on with new submarine tactics and eqpt, same thing here w/ medicine.
So he presents the BO offer to shareholders and he votes against it - what good did presenting it do? Sure, it allowed all to see how shareholders feel, but it doesn't mean he has to do the deal if he doesn't believe it is a responsible offer based on the value he perceives due to upcoming new indications, multiple BP talks in progress, or any host of other possibilities.
Wrong, Leo has a poison pill that gives his shares voting rights that exceed all other votes together.
Also, there are quite a throng of longs that support Leo and would vote their shares however he believed best. I am among them.
I think IPIX is not your normal company in that it has a large core of investors, not traders.
However, if Leo was getting bids in the billions the share price will have surely risen to a point that all stockholders that wanted to cash in could and have a tremendous return on their investment. Win-Win.
Tomorrow should be quite a day as the trader/raider who tries to destroy our stock price regularly has issued about 5 or more calls to his minions this weekend so they should be pumped about something.
Personally, I would be hesitant buying at the open because they normally spike it up early pretty good then open the trap door and kill the price as they did last Friday.
Now if we get any sort of good news, watch out.
In the long run, a bad day or two won't stop the meteoric rise of the stock over the next 2 months IMO but I sure would like to see this guy and his crew get hammered so they leave IPIX alone for awhile.
It was all in the quarterly reports (8K, 10Q,?) - I am not up on financial reports.
But it was about 2 years ago and the report came out definitely in July or Aug. Shouldn't be too hard to find the indication.
Remember, this was the report that listed 3 major developments or targets and IPIX said they would make them all and then the falling thru of this deal kiboshed it all and they made none.
Had to have been OM as it was the only one far enough along at that time.
As to OM, IPIX has already perfected the delivery system via sachets (granular Brilacidin). Evonik is their manufacturer. Evonik is worldwide. P3 for OM shouldn't be that terribly large as there is no worry about systemic buildup. Also should be very short as each patient only has to take B-OM for about 6 weeks. So assuming IPIX has the funds to do the P3 themselves (which I think is a no brainer that they do) the value of the indication goes up tremendously after it shows success in the P3 trial.
There is no current medication or treatment for OM worth squat. So it shouldn't be hard to get doctors to use a totally safe product that could prevent death or unbearable pain caused by OM.
Maybe Evonik partners with IPIX in both mfg and distributing B-OM worldwide and split the revenue or something more in favor than that for IPIX. Hell of a lot better than taking 15% from a BP that took no risk, offered no help, didn't input any information as to product or delivery system, and basically is just selling the product.
IMO, IPIX should take OM by themselves. The product will sell itself, the product is easy to mfr, ship, store, and for patients to take at home with no pain or mess.
As for the other products, the only one I can see them taking to market is the CV as sales will mainly be to governments or large hospital systems. All other indications, take thru P3 alone whenever possible financially and IMO that will be most of them.
Look for the same pattern as always (Fri was a good example). Major rise in the first 15 minutes or so and then the bottom falls out a short while later. Picks off the newbie flippers and the stock should again start heading northward by noon.
You keep saying we need testing by getting B into animal and human trials. It has been tested in over 500 human patients to date, though not specifically for viruses. Why would you assume no negative side effects or lack of efficacy in all these trials for other indications wouldn't lead to expectations of a great transfer from in vitro CV testing to human trials? Why do we now need animal testing when we have loads of human testing?
The ABSSSI testing alone saw B work thru the entire body with no bad side effects, efficacy has been shown in all trials, and the tests for CV to date have been spectacular.
I don't mind a bit of ol' Missourian "show me" but I don't like someone trying to continually rain on my parade.
Everyone is aware of the need for successful human trials in CV, but all this crap about the needed multi-steps to get to that point is baseless IMO. It has been tested in kidney and lung tissue, it worked great. Get it in now to humans in doses that won't have negative effects on the body per the ABSSSI data and that should be done within the next 4 weeks IMO. Anything else is putting lives at risk needlessly IMO.
You keep talking about your other great CV drugs coming on line. We have listed the many features of B on this board, would appreciate you posting the features of whatever drug you want to review that you think shows more promise than B.
Brilacidin-IBD pill was run for safety only on healthy human patients recently to make sure the new delayed-release technology would allow the pill to pass thru the stomach and the small intestines and release B into the colon so that it can be used for IBD treatment. It is now ready to be run in a P2 for ulcerative colitis and had been scheduled for such a trial to be started this summer, but due to CV now more likely for Q4. Just as the human lung test results for CV were the watershed results necessary to propel B forward for CV, this IBD trial for colitis IMO is the watershed data that will cause BP to throw BIG money at IPIX to become a partner for the IBD partnership. So that is another $70B market we could be looking mighty attractive to by the end of the year.
Results of the trial using Oralogik Technology by BDD was put out in the IPIX 13 Feb PR ( to which I have attached the link).
Note in the PR if you look at the pictures of the torso it shows how Brilacidin was released in the colon and supports that it can be programmed to be released anywhere in the colon necessary (different release points for colitis, Crohn's, or proctitis).
http://www.ipharminc.com/press-release/2020/2/13/innovation-pharmaceuticals-phase-1-trial-of-brilacidin-for-ulcerative-colitis-meets-primary-endpoints-positive-topline-results-of-oral-brilacidin
You made the following comment:
"Will feel more confident as we progress that we understand HOW it works as an antiviral."
It works thru 3 MOA's as evidenced in the update section of IPIX website.
You act as though B just popped on the scene in March. It has been around and has been thoroughly studied for years. Don't understand your logic.
Prurisol is an excellent example of how drugs were developed prior to computers; in a lab by a few doctors with very little discovery of pros, cons, or interference when introduced into the human body.
It is also why all the drugs tested to date for CV19, those FDA approved up to decades ago, have failed so miserably in providing any form of cure or treatment for CV19.
Brilacidin is a NEW ARM OF MEDICINE, PEOPLE!! (directed at newbies KMBJN, not you)
Developed using tens of thousands of hours crunching data thru super computers to maximize pros, minimize cons, and ensure that test data will translate positively into human trial results.
Apples and Oranges entirely between Brilacidin and EVERY other drug tried to date.
I will admit there is always some risk, but it has been reduced to a level I believe is akin to what the 3 MOAs provide in preventing viruses to build up a resistance to Brilacidin: instead of 1/1billion for drugs w/ only 1 MOA,Brilacidin is 1/(billion x billion x billion). Brilacidin's background of formulation takes the risk down as well to a low level never seen before in medicine.
Also ask how many peer reviewed articles have come out of the RBLs to date. Last I heard it was none.
Yet here is B looking at 2 on the near horizon and a request from one of the RBLs for study as a PAN-CORONA.
I had heard that the granular B for OM was quite easy and inexpensive to mfr but that the IV was tricky and costly. Not sure who said it so take with a grain of salt.
I scratch my head as to why everyone is so intent on selling IPIX when it could possibly become the largest paying "dividend" play available.
I know since today we have no commercial products and revenue is zero dividends don't cross the minds of many, in the future that should all change.
Let's look into the future 3 years from now: Brilacidin is now a major factor in IBD, COPD/Asthma, Kidney infections, dermatology uses, OM, brain inflammation, burn cases, CV19, Flu, and all other viruses, etc, etc.
Kevetrin has been developed into a pill and has been in a flurry of complementary trials with all current cancer treatments and as a stand alone product. I believe that is still a large ? to all but IMO it will be found to be quite effective and thus very, very valuable.
Who does not think both Brilacidin Kevetrin with both their efficacy and safety profiles will not be able to take a very nice piece of each of these areas of medicine?
So just for the sake of establishing a scenario, say they capture 25% of each market.
Say for the scenario they get a royalty rate of 20% (some may think this is high but I don't see Leo partnering any indication prior to P3 so with their safety profiles the risk should be about gone and the BPs should pay a higher than normal royalty rate.
Again, for this scenario lets have shares at 333MM and revenues at $5B/yr (I again think this is quite a conservative scenario).
What would expenditures be for a company with less than a handful of employees or only a greater number mainly in accounting areas, no facilities, no healthcare or retirement benefits of note to pay, etc? For the amount of revenues, expenditures will be next to immaterial at that time.
So take $5B/333MM shares and that is $15/yr in dividends.
I will again go hogwild conservative and cut the dividends to $10/yr. (This effectively reduces revenues to 3.5B/yr or so)
So a person with 50K shares would be receiving $500K/yr.
A person with only 10K shares $100K/yr.
Personally, that leaves many of us with large holdings having generational wealth in that it never has to be touched as the dividends alone should provide a great lifestyle for anyone.
The above is why I am not hellbent on selling the company right away.
But then again, I am an investor. Most of those now on the board are traders and want to make a quick buck and run. Leo isn't among them.
Leo has a poison pill that gives his shares the overall say in whatever happens to IPIX. All of us other shareholders could say sell the company and if he says no go, the sale doesn't get done.
And Leo has said many times he is not selling the company prior to seeing it reach proper value.
Just as he said for years "no, no, and no" to a reverse split but still jackwads kept saying to expect a RS.
Leo has shown many times he does what he says.
As I saw in the corporate world, all companies view the opposition by looking at their strengths and building them up in many cases unrealistically. They also look at themselves focused on their main weaknesses. Totally cockeyed, but that's what I saw as a rep looking in on the many companies I represented.
Now take Brilacidin for CV and compare it to ANY opposition and I have the attitude of "show me" not some good facet or two but the WHOLE PICTURE because that is what they are seeing. B's strengths are overwhelming, period!
3 MOAs to kill virus
Anti viral, inflammatory, and bacterial
Immunodoulatory properties
SAFE in all clinical tests to date
Transfers exceptionally well lab test data to trials in humans
Stops replication
Shown effective to date in kidneys and lungs
Effective in bowels in other clinical trial so should transfer quite well for CV19 in bowel as well
Anti-inflammatory for brain
AND THE KILLER - RBL wants to run a PAN-CORONA TEST against the spectrum of ALL corona viruses, encephalitic alphaviruse, and filoviruses. Everyone in medicine must be looking at Brilacidin as a super star and wondering how this gem has been kept under wraps this long.
So IMO all others are sad imitations of the total package, Brilacidin. Not saying they may not prove effective in some way, but trying to say they have advantages above Brilacidin is pure horse droppings IMO.
We know what we own, and test results and known properties of B today show it to be the giant all the others are chasing.
I still think you are way under Leo's target buyout price.
He was at 15B or more prior to clinical trials.
Now that most all the risk is behind us, he is going to be rewarded for going it alone.
BP hasn't done sh** to help us, no need to let them get the goods now for anything less than paying thru the nose.
Pretty sure we will have a bidding war when B or IPIX is put up for sale.
At that time, the naked position will also be quaking in their boots and trying to get out of their predicament so again possible strong surge up (since nobody knows the true extent of the amount of shares of which we are speaking).
Your thinking shows you haven't been around long. CEO, who has total control of a buyout, won't be selling at that time unless someone coughs up many, many billions and it seems too early for that to happen yet.
Maybe in the next 2 years, but Brilacidin has a long way to go to show its full power and revenue-producing potential. Why sell now when it will only get much more valuable in the future?
CEO is not a trader or interested in getting richer (as he knows he already is mega rich with IPIX today) so don't expect a quick sale.
As I posted a while back, you don't sell a gold mine after you find the first big nugget. You have to analyze the whole field before determining when to sell and for how much.
All any startup bio wants is a win-win.
But the way the system is set up the norm is a win-rape in favor of the BP.
IPIX is not in the position, though, of having to bend over to please a BP for funds to keep Brilacidin moving forward. In fact, the whole CV19 / pan-corona applications could be handled directly by IPIX selling to governmental agencies and result in massive revenues for IPIX on a yearly basis.
AS dire as CV19 has been and continues to be for the world, it has been a blessing for IPIX and bringing Brilacidin to life in an immediate fashion.
The world will be a lot better once Brilacidin can do its work on numerous areas of severe medical concern at the present time.
Many here think next week to possibly 3-4 weeks or so is a more fitting time for receiving grant money.
Have to remember that our grant application is being supported by the GOVERNMENTAL regional bio lab that did the testing and is part of the organization issuing the grants.
Nice to have insiders on your side.
I think you are very light with this guess.
First off, once B gets certified as the go-to treatment for CV19, what revenues do you think that would generate per year? What is a solid guess as to patients per year worldwide? I would think a minimum of hundreds of thousands. Multiply that by cost/patient. I don't have a good guess as to that but lets just say $200/patient.
Now add in value should B prove to be a success for PAN-CORONA and that includes flu cases / year. Would people take the current flu vaccine knowing that many years the experts are wrong as to which flu strain will be prevalent or would they go for a dose of Brilacidin knowing that it kills ALL coronaviruses?
With the success in lungs for CV19 treatment, what would that translate into for other lung conditions such as the $70B/yr market for COPD and Asthma?
What value / yr for kidney issues as B was shown to be a strong deterrent to kidney problems?
What value for IBD with its yearly $50B/yr revenues?
What other problems will Brilacidin attack? Dermatology, ear and eye drops, and whatever else they come up with. Just recently we heard that Brilacidin should be extremely helpful for serious burn patients.
So one can see setting a value on B now is ridiculous. The range of its uses is now just being realized so giving it a value now is impossible, but it is large.
What would you set as a value for the entire Brilacidin platform? IMO it is more in the $30B range or higher. I may be too optimistic, but at this time unless someone wanted to play in my ballpark price wise I would tell them we will keep it at the current time and let the indications roll out over the next few years.
The revenues we should get w/ CV19 alone make it a whole new ball game. We don't need the BPs as much as they need us.
IPIX as of today IS NOT the IPIX of last year, last month, or even last week!!!
Prior to Wednesday the very, very small base of true longs were the only people that were really tuned into the near magical powers that Brilacidin, the best of a new arm of medicine being comprised of defensin mimetics, possessed!
Due to financial constraints, IPIX/Brilacidin was creeping up on medicine thru many successful clinical trials, but these were not the type of advancements that took the public by storm, even though they were quite momentous( as in the pill form of Brilacidin for use in combating IBD (Irritable Bowel Disease).
But Wednesday finally exploded Brilacidin on the big screen of worldwide medicine by way of showing its power in dealing with CV19 in a govt lab test of human lung tissue.
The trading patterns of the past are gone! Sure, the stock will most likely still be quite volatile due to large hedges many believe have been played by some investors betting the company fails, but NOBODY can take away the success of the CV19 lab tests or again hide Brilacidin and IPIX from the eyes of medicine worldwide.
All investors need to quit acting like scared rabbits. Know what you own and be confident that whereas in the past the tail was wagging the dog, IPIX has now become the BIG DOG and never again can it be returned to the shadows.
Brilacidin is now the shining new sun in the world of medicine. Embrace it, take joy in it, and quite worrying about day to day meanderings of the stock price.
The grants are coming, no ifs, ands, or buts. A successful human trial will follow and that is the FINAL test to show Brilacidin will be a life changing drug for CV19, many other areas where Brilacidin will relieve worldwide pain and suffering, and bring GREAT rewards to stock holders. Past trials make those that have been following Brilacidin closely for years believe our chances for success are overwhelmingly high. Remember, this drug was not a hit or miss idea in a lab with a small number of doctors working on it, it was derived after thousands of hours of data being crunched on super computers to make sure all possible bugs in it were worked out prior to its final formulation.
Brilacidin is going to reek havoc with quite a number of BPs IMO.
I have always thought one or more have been the main antagonist(s) trying to drive IPIX into bankruptcy.
Didn't work, now I hope we bury them.
In reviewing my post on the many additional benefits of Brilacidin and the current investigation of it by govt RBLs (Regional Bio Labs) I realized I missed some very important additional benefits of the investigation.
Brilacidin appears to have a wide spectrum of uses in the body. As such, it will have to undergo FDA clinical trials for each application (called indications in medicine) and these trials are very costly and time consuming. The current CV19 testing will establish a broad base of data providing a clear safety profile of the drug which will down the line allow future trials to be run with fewer patients and possibly for shorter periods of time, thus saving IPIX quite a lot of money and bringing Brilacidin to market in a lot shorter time for each indication. Big, big savings.
As an example, the wonderful news regarding Brilacidin working in lung tissue should also provide a strong basis for looking at B for use against COPD and Asthma, about a $70B/yr market. The kidney results should aid in many severe kidney problems and also for use in severe burn cases as many systems crash during such times and Brilacidin would be able to help in many of them, to include kidney shut down.
Prior to the covid crisis, B was not being pushed yet as an antivirol and many longs thought all that would come of the testing would be some free data and possibly a bit more exposure for B, but now it should be exploding on the world medical scene as one of the most promising drugs of all time as its properties are fully understood by medical professionals.
Good example is the flu. Current vaccinations are at the mercy each year of the experts deciding which strain of flu will be dominant and they make the vaccine to kill just that strain, often being wrong. Brilacidin kills ALL strains of flu, so using it is a sure deterrent to getting the flu, not a hit or miss proposition as with the current system.
In the realm of aiding against bacteria, to date IPIX has worked against about 93 strains of bacteria to include 9 strains of anthrax, the black plague, and other severe types. To date, it has not failed in killing any bacteria strain against which it has been tested.
Brilacidin is on the verge of a P3 trial for Oral Mucositis and has been developed into a pill form that releases the medicine into the large intestine (bowel) that should work against all types of IBD (Irritable Bowel Disease) to include colitis, proctitis, and Crohn's Disease. It is expected to have many dermatology-related indications.
The only thing holding back rapid development of this drug has been money, for a staggering amount of money, about $1B and time, about 10-12 years, is needed to bring a new drug to market.
In a personal vent, IMO this is pure BS as it makes startups go thru a Big Pharma who takes the vast majority of the revenues and little goes to the firm who had the genius to develop the drug. Same ol' same ol' where those with big money and lobbyists control DC and the federal agencies making the rules so the rules are all written for their benefit.
IPIX has a chance to be one of the very few startups that can become a major player, akin to what Regeneron has done.
Most longs feel the great majority of the risks for IPIX to succeed are behind us, the future is bright and extremely promising.
The only real test to come is how it performs in the human trial for CV19 but confidence is extremely high that it will do a superlative job as it has done in all prior trials. This confidence is based on the solid safety profile it has established over many prior trials for other indications, its consistency in those trials of being able to translate in vitro success into in vivo success, and the fact that it is a new arm of medicine that was designed using super computers to make sure it would perform as expected. This is not your old drug design from the past where a handful of lab personnel had to run each idea thru trials using mice or other animals, the computer allowed billions upon billions of formulations to be tested to arrive at the ultimate end product.
Many will say we had quite a major day yesterday. It was a good day, but it was only a beginning. I expecdt many such days to follow with some daily increases being much greater.
Take your time to do DEEP DD regarding IPIX, it could be the investment of a lifetime.
Today's PR/news about Brilacidin is going to cause a lot of eyes to be turned to IPIX. The problem is that even though the initial glance at the headline to see B killed 97% of CV19 in human lung tissue is astounding, it barely begins to tell the true story of the many, many positive features of this wonder drug.
Government RBLs(Regional Bio Labs) have independently confirmed that B killed 85% of CV in kidney tissue and 97% in lung tissue. Amazing! But it gets better.
The RBLs also collaborated on a requested grant for IPIX for a PAN-CORONA investigation, meaning they wanted to investigate it for far wider uses than just CV19. Why would they do this?
The grant submission included testing for brain inflammation (encephalitic alphaviruses) and filoviruses (Ebola and Marburg), the deadliest type of viruses.
They wanted a PAN-CORONA because they wanted to test ALL coronal viruses to include ALL types of flu (asian, swine, avian)and assorted other classes of viruses. Brilacidin could become the world's major vaccine component or a treatment for any type of virus. We expect that two peer review articles (1 from each RBL) to be published soon will cast more light on the positive results that gave rise to the PAN-CORONA request. Wow, could it possibly do even more? Yes, lots more.
What good is an effective drug if it is not safe? Don't TV ads for drugs that take most of the time telling you about their terrible side effects scare the he** out of you? Not to worry, Brilacidin has gone thru lots of clinical trials to date and has shown NO serious side effects, including a lack of toxicity in all CV19 testing at the RBLs. Is there more?
Yes - other major problems that occurs with CV19 is the body developing its own defense particles in the blood in such numbers that they overwhelm organs and that leads to death. B has immunomodulatory properties that keep this from happening as evidenced in the RBL testing.
The other major are of benefit is that Brilacidin is antibiotic (bacteria), anti-inflammatory (inflammation), and antivirol (viruses). There is NOTHING out there that touts these features in one drug.
The final strength of Brilacidin is that it has 3 MOAs (method of action) of how to kill the CV19 virus. What this means if that if CV19 has a 1 in a billion chance of mutating to stop the effectiveness of a treatment, since B has 3 the chances would drop to 1 in a billion CUBED ( or 1/ 1000000000 x 1000000000 x 1000000000)
How can Bilacidin be so overwhelmingly effective and safe yet we haven't heard about it yet? Brilacidin was possibly the first drug that was developed using near AI (artificial intelligence) to maximize its benefits and minimize the side effects using thousands of hours crunching data on a super computer. Thanks to geniuses at the U of Pennsylvania, this new class of medicine (defensin mimetics) was discovered and B is the king of the ensuing drugs founded. When the CV problem came to light, the govt thru all the money at the Big Pharmas and their outdated library of drugs that were at times 30 years old or more and tried to have these repurposed for CV19. Good luck with that thinking. IPIX, a startup BP, didn't have the backing of everyone since they don't have full time lobbyists as is the norm now in the swamp (DC and politics) so to date these useless BP drugs have gotten all the money.
That is just about to change. When B finally gets its grant from govt, it will be able to quickly be placed in a human trial and lives will be start to be saved.
Today was a nice day, but a drop in the bucket in the near future for the success of both Brilacidin and IPIX.
I will not even go into the other drug IPIX has had to be tabled due to lack of finances which again will be able to restarted with the expected revenues in the near future.
The expected publicity of this PR data, namely identifying Brilacidin to the general public WORLDWIDE, should begin today. Can't see how medical authorities will not see B should be the leading candidate for CV19 treatment at this time.
97% kill rate amazing, no toxicity even better, no cytokines a plus next to very, very few possible treatments will be able to duplicate, and another major plus - B in IV form already being produced. Govt will have to ramp this up quick, very quick and very intense production.
This may be the straw to break the camel's back for the govt to throw full support behind B and getting it into human trials NOW. I don't think we will have to wait a month to get funding, I believe govt knows with this data they will be brought to task if B in a human trial is delayed for the peer review (as the data came from their own labs and one would hope they know what they are doing), the public has seen untold massive funds given to pure SH** BP drugs for repurposement, and the public will no longer tolerate govt BS to allow continuing numbers of US citizens to die.
Govt has to have had the basics of a human trial already mapped out just for such news as we received today and so that they can get it into the most critical part of the testing immediately.
If no foreign country jumps into help, I also break our ass to help them when IV becomes available, especially China. Don't give them any, just like they did with masks and such for us.
If we get good results from the expected human trial testing for CV19, I wonder how many areas that will allow Brilacidin to be prescribed for Compassionate use? Or would doctors even start requesting such for Compassionate use?
Major/severe cases regarding burns, kidney issues, lung problems, biological issues, head issues, septis, etc?
Once one is near the end of the line, the patient or their family would most likely grab at any possible aid. Brilacidin would certainly fill the bill.
Or would IPIX not look kindly on that in case it didn't work and B started getting a bad reputation?
Any chance Brilacidin could be used as a general IV for all severe cases in ERs since it would provide hydration with great additional benefits and not any real adverse effects?
I don't think Brilacidin in IV form is all that cheap to mfr but it seems in many, many cases the use may be justified.
One of the main reasons for a peer review is to have validation for data submitted for grants. Since many have been saying that the time for testing seemed to have taken so long, IMO there could be a chance that the delay in sending the test data to IPIX (which must have come in about 7-9 days ago based on PRs) was due to the peer review articles being written up and submitted along with the raw data.
This would be logical so they could submit them with the grant request and, if they got them out right away, peers could respond with a copy going to the proper govt body doing the grant approval to validate the data.
Makes me realize then that the door for publication of the peer articles could be wide open, as early as next week or any number of weeks thereafter. I will hope for the shortest time possible.
Regional bio labs are government labs, government says they want a fast response to CV crisis, so I do not expect peer review articles to see too much delay in being published.
Not sure about what the investigating procedure was, but wouldn't you think it involved having CV19, kidney tissue w/ CV19, and lung tissue w/ CV19 in various petri dishes or the like and then introducing various dosages of Brilacidin and using some set method to determine the amount of CV19 that died, reproduced, or other such events? Maybe use successive treatments on the same tissue to see if more than one treatment w/ Brilacidin did any good or caused any problems and other questions like this they may have had.
Doesn't seem that involved to not be able to put in a table the resulting data and then form charts that exhibit the positive or negative responses to such treatment.
It's not like they are trying to figure out a guidance system to Mars and back.
No disrespect to the RBLs intended, just don't think data that hard to examine and determine as to positive or negative response to Brilacidin.
Didn't realize there were a number of drugs out there that have activated p53, are safe, and should be highly complementary to just about any current cancer drug treatment out there today. Too bad Leo doesn't know what you do about K so as not to waste any further money on developing it as, in your words," it will be surpassed by any other drug out there". Hard to believe cancer is still such a major problem with all these world beating cancer drugs available already. Will have to tell the Cancer Foundation to start cutting back on raising so much funds for study.
Also don't know your definition of a great drug. The largest selling drug, Humira, is a biologic and all biologics have MANY problems by nature, are quite expensive, and supposedly lose their effectiveness after a couple of years.
I have never heard of your two named drugs in the news as world beaters, but then I don't delve too deeply into medicine.
Your efforts to try and sell off IPIX for pennies on the dollar and belittling drugs before they have even had a chance to be fully investigated make me go "huh?" . Seems to me you are quite convoluted regarding IPIX, singing its praises one day and then turning right around and belittling it the next.
The last PR said that BOTH regional bio labs would be submitting peer review articles on their Brilacidin investigations.
Many of us have been overjoyed with this, saying it points to some excellent findings as the labs are seeking corroboration from peers in the same field. Obviously, if findings were negative there would be no need for peer review.
I recommend everyone read the article (it is short) and realize the importance of these articles and how they should solidify without a doubt to the entire medical community the strengths of Brilacidin and greatly expand the knowledge of Brilacidin by that said community.
www.medicalnewstoday.com/articles/281528#process
(you will need to copy and paste the linked article)
From reading the article, all the article is is a reporting of what investigation was done, how it was done, and results of said investigations and for peers to try and find any fault with any part of the investigation. Should not take that long to get out IMO.
Leo has been steadfast over the years that he is not interested in selling the company until we have total valuation for B and K and that will not be known for some time. Thus, I don't see any possibility for a buyout in the near term. Maybe a couple of years out at the earliest, but most likely even longer.
With revenues continually ramping up over the next ongoing years as we get more and more indications commercialized, why be eager to sell?
Leo (and stockholders)are going to have a lot of money down the line whatever Leo does, so I don't see that as the driving force for his plans for the company. I think he wants to leave a legacy with IPIX as a startup that was wildly successful and brought two of the greatest drugs known to man to market.
Many people have money, few are legends. Leo thinks big.
My WAG
IPIX had another great week last week.
So where does that leave us at the present moment, especially in relation to news we can expect in the near term or further advancements along any front?
It is my belief that news may be scant for a few weeks since I expect no further news on testing prior to release of the peer-review articles forthcoming by the RBLs. They had to have finished their testing last week so that it could be tabulated and included with the grant request that was said by Leo to be submitted Friday or this weekend at the latest.
I think we have a minimum of 2 weeks until these articles get published and, if anything, this time frame is too optimistic.
The grant money was just submitted and I would think for the amounts we are trying to receive this will take at least a month. Again, no clue but if anything expect more time needed rather than less.
I take the above time frames as minimums as we haven't had anything go thru quickly in these tests except the kidney tissue testing.
I believe our other areas of development, OM P3, IBD P2, Kevetrin pill formulation, LW, etc are all either on hold or pushed back while focus is on CV development for Brilacidin. I can't see any deals coming thru while CV results up in the air as what path Leo will follow will be almost totally dependent on CV grant money and if it looks like B as a CV treatment looks probable, possible, or unlikely based on human trial. Any kind of success in the human trial will change the financial fortunes of IPIX in a heart beat and allow Leo to determine the path he WANTS to take rather than taking a path he HAS to take.
Bottom line: EVERYTHING BOILS DOWN TO RESULTS OF HUMAN TESTING FOR BRILACIDIN AS USE IN CV19 AS A TREATMENT.
No amount of test results can guarantee human trial success, but the near AI (artificial intelligence) development of Brilacidin via the use of thousands of hours crunching data on a super computer puts it heads and shoulders ahead of ALL other drugs being tested in being able to transfer results from in-vitro testing into human testing.
The next month may be fairly quiet for IPIX in PRs, but not in Brilacidin advancement. The grant requests are being evaluated, the peer articles are being written, the spread of word at least in RBL circles continues, IPIX is in near shut-down mode as far as expenditures are concerned, and I expect other drugs to continue to fall by the wayside during this time.
I expect a lot of criticism and FUD being tossed around by some with probably ridiculously low valuation opinions being mentioned. All I will say about that is I believe in Leo, he is the only one that has the information as to what B and IPIX are worth, and he will set the value of any deal, no one else. I will trust what he recommends as to the future of IPIX.
As to further developments for OM/IBD, I expect them to continue this year but not necessarily right away.
Let things play out in the orderly manner they have been progressing since the start of the CV testing. We are near getting grants (we all know that is pretty much a given), we are near getting human trials started (again a given), we are near learning more about the testing recently completed via peer articles and what sparked the interest to have Brilacidin investigated as a possible pan-corona treatment, and all we as stockholders have to do is wait patiently for the process to finish, and the finish line is now in sight IMO for sometime by the end of the summer, late September, and I consider the end line some word on results of human trials of B for use as a CV19 treatment.
If there is any change to the above, I expect it to be to the even more optimistic side. I stress that I could not be happier than I am as to where IPIX stands today and their odds for success in the future. I am convinced Brilacidin will become the wonder drug so many of us expect it to become.
I have already reached my dream position (stock-wise)in IPIX but already know I will keep adding thru the summer as I don't see price going up much (at least until grant money approval)and what I see in investing in IPIX now is it is better than letting free cash just sit in a bank account.
Just read warrenthomas' post about a family member with severe burns. Hope a miracle comes thru. Chalk up one more possible use for Brilacidin, per his medical experience, in helping patients with severe burns.
I watch a lot of youtube dancing, especially Boogie Woogie, Shag, Carolina Swing, etc. Europeans are into these American music forms of dancing much more than Americans seem to be.
Had a guy at our golf course that was a real biggie in USA Ballroom dancing and I asked him how you could judge the national finalists as they were all so good.
He said when you knew what to look for the winners were usually heads and shoulders above all the others. Kind of like diving, gymnastics, ice skating where everything is so judgmental instead of quantitative as in time, distance, height, etc.
PR yesterday said labs were going to be submitting peer-review articles of IPIX testing.
What do you think is going to be in those articles?
Obviously, it will be the results of the testing done at the labs regarding IPIX and CV19 with lung and kidney testing data, in addition to whatever else they found. They had to have found something pretty darn impressive to submit a grant for a pan-corona testing plan.
So would you expect them to give Leo the right to divulge the results of the tests prior to their papers coming out?
Are the results expected to be positive?
The RBL is working with IPIX in submission of the pan-corona grant request and data from the testing has to be part of the grant request so obviously the results are positive, IMO quite positive.
The labs want recognition, they don't have stockholders desire for results as one of their main (or least)concerns so we will find out about the test results when the peer-issued articles are released, not before.
I would assume they spent most of this week formulating the data for the grant request since they were to submit it this week.
As multiples said in a prior post, everything orderly and not done in haste.
To whom it may concern: 207 did not check out
When stock pricing goes out to 5 digits, it seems more than retail is involved. We know it isn't institutional, so what is left?
Hope you were able to add significantly to your position the first half of this year.